Kexing Biopharm (688136.SH) submits H-share issue application to Hong Kong Stock Exchange and publishes application materials.

Kexing Biopharm (688136.SH) announced that on November 6, 2025, the company submitted an application to the Hong Kong Stock Exchange Limited ("HKEX") for the issuance of H shares and listing on the main board of the HKEX. The application materials were published on the HKEX website on the same day. The application materials were prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission ("SFC") and HKEX. They are draft versions, and the information contained in them may be updated and revised in a timely manner. Investors should not make any investment decisions based on the information included in the materials.